IRIS
Della Porta, Matteo Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.405
AS - Asia 4.589
EU - Europa 1.511
SA - Sud America 693
AF - Africa 224
Continente sconosciuto - Info sul continente non disponibili 138
OC - Oceania 16
Totale 16.576
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.140
SG - Singapore 2.785
CN - Cina 873
BR - Brasile 560
VN - Vietnam 383
IT - Italia 361
FI - Finlandia 283
IE - Irlanda 203
NG - Nigeria 160
CA - Canada 159
HK - Hong Kong 147
DE - Germania 121
FR - Francia 118
GB - Regno Unito 109
IN - India 86
NL - Olanda 76
SE - Svezia 56
JP - Giappone 48
MX - Messico 47
TR - Turchia 43
AR - Argentina 40
BD - Bangladesh 36
IQ - Iraq 34
ES - Italia 32
PL - Polonia 26
ZA - Sudafrica 22
RU - Federazione Russa 21
BE - Belgio 20
CL - Cile 19
EC - Ecuador 18
CR - Costa Rica 16
PK - Pakistan 16
CO - Colombia 15
VE - Venezuela 15
UA - Ucraina 14
JM - Giamaica 13
SA - Arabia Saudita 13
AU - Australia 12
ID - Indonesia 12
KR - Corea 12
PY - Paraguay 12
UZ - Uzbekistan 12
JO - Giordania 11
PH - Filippine 11
IR - Iran 10
KE - Kenya 10
MY - Malesia 9
GR - Grecia 8
AE - Emirati Arabi Uniti 7
AT - Austria 7
CH - Svizzera 7
MA - Marocco 7
PE - Perù 7
BG - Bulgaria 6
CZ - Repubblica Ceca 6
NP - Nepal 6
DK - Danimarca 5
GT - Guatemala 5
KZ - Kazakistan 5
LT - Lituania 5
TH - Thailandia 5
TN - Tunisia 5
EG - Egitto 4
HN - Honduras 4
IL - Israele 4
NZ - Nuova Zelanda 4
OM - Oman 4
PA - Panama 4
AL - Albania 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
KH - Cambogia 3
NI - Nicaragua 3
NO - Norvegia 3
PR - Porto Rico 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
CI - Costa d'Avorio 2
EU - Europa 2
GY - Guiana 2
IS - Islanda 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MR - Mauritania 2
PT - Portogallo 2
SN - Senegal 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BS - Bahamas 1
DZ - Algeria 1
EE - Estonia 1
Totale 16.424
Salva come PNG Salva come JPEG
Città #
Singapore 1.349
Wilmington 1.030
Chandler 954
Ashburn 516
San Jose 496
The Dalles 411
Shanghai 370
San Mateo 356
Helsinki 282
Ann Arbor 246
Council Bluffs 240
Dallas 231
Dublin 201
Beijing 188
Boardman 186
Princeton 173
Leawood 165
Lawrence 160
New York 160
Benin City 159
Milan 144
Hong Kong 133
Santa Clara 130
Woodbridge 123
Los Angeles 117
Ho Chi Minh City 116
Fairfield 101
Hanoi 101
Paris 93
Amsterdam 65
Rome 60
São Paulo 59
Houston 58
Toronto 57
Phoenix 54
Buffalo 50
Seattle 44
Tokyo 41
London 38
San Diego 33
Charlotte 31
Montreal 30
Chicago 28
Brooklyn 26
Orem 26
Columbus 24
Falls Church 24
Haiphong 24
North Bergen 24
Norwalk 24
San Francisco 24
Cambridge 23
Boston 20
Brussels 20
Philadelphia 20
Warsaw 20
Atlanta 19
Kocaeli 18
Miami 17
Redwood City 17
Da Nang 16
Redmond 16
Rio de Janeiro 16
Monmouth Junction 15
Belo Horizonte 14
Chennai 14
Mexico City 14
Stockholm 14
San José 13
Brasília 12
Cleveland 12
Falkenstein 12
Washington 12
Baghdad 11
Figino 11
Frankfurt am Main 11
Kingston 11
Las Vegas 11
Nanjing 11
Tashkent 11
Curitiba 10
Hillsboro 10
Mumbai 10
Naples 10
Pune 10
The Bronx 10
Turin 10
Amman 9
Guangzhou 9
Jacksonville 9
Johannesburg 9
Manchester 9
Milwaukee 9
Pittsburgh 9
Queens 9
Richmond 9
Tappahannock 9
Assago 8
Athens 8
Detroit 8
Totale 10.390
Salva come PNG Salva come JPEG
Nome #
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 219
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. 146
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 142
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 128
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 127
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 126
Costimulatory molecules and immune checkpoints are differentially expressed on different subsets of dendritic cells 125
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 123
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 122
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 120
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 119
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 118
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006 Nov 1;107(9):2206-11. PubMed PMID: 16998940. 117
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML 116
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 115
CD34 and CD2 expression in acute promyelocytic leukemia. 112
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 112
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. 111
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. 111
Classification and prognostic evaluation of myelodysplastic syndromes 109
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 107
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 106
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 106
Leukemic transformation of polycythemia vera: a single center study of 23 patients 105
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 104
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. 104
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 101
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 100
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 98
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 97
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. 96
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 96
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 96
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 96
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) 95
Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. 95
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 95
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 95
Importance of classical morphology in the diagnosis of myelodysplastic syndrome. 95
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 95
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. 94
Prognosis of secondary acute myeloid leukemia 94
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 94
Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). 94
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 94
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 93
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 93
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 92
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 92
Differentiation of follicular dendritic sarcoma cells into functional myeloid-dendritic cell-like elements. 92
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 92
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 91
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 91
Clinical and biological implications of driver mutations in myelodysplastic syndromes 91
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 91
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 91
Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients. 90
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 90
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 90
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 89
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 89
Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. 89
The Genetics of Myelodysplastic Syndromes: Clinical Relevance 88
Dendritic cells in acute promyelocytic leukaemia. 88
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 88
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. 88
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 88
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 87
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 87
Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 87
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 86
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 86
Myelodysplastic syndromes and bone marrow microenvironment. 86
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 86
Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. 85
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 85
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. 84
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 84
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 84
Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. 84
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS 84
Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. 83
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 83
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 83
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 83
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome 83
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study 82
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 82
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients 82
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 82
Simian virus 40 and lymphoproliferative disorder. 82
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 82
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia 81
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 81
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 81
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes 80
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 80
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 79
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 79
Opportunities and Challenges of Synthetic Data Generation in Oncology 78
Totale 9.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.201
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.201
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022953 0 0 0 213 23 26 29 132 105 70 323 32
2022/20232.634 374 85 210 325 252 237 5 234 493 210 176 33
2023/20241.356 121 178 278 47 27 115 57 149 20 46 167 151
2024/20252.000 58 51 24 42 22 275 77 238 255 511 234 213
2025/20265.468 880 275 253 433 179 212 1.706 309 289 352 231 349
2026/20272.219 384 516 862 457 0 0 0 0 0 0 0 0
Totale 16.576